Asia Pacific Ophthalmic Drug Delivery System Market Report 2022: 8.9% Annual Growth Driven By Prevalence of Ophthalmic Diseases & Emerging Novel Ocular Drug Delivery Systems - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Asia Pacific Ophthalmic Drug Delivery System Market 2021-2031 by Product, Dosage Form, Disease, Setting, and Country: Trend Forecast and Growth Opportunity" report has been added to ResearchAndMarkets.com's offering.

Asia Pacific ophthalmic drug delivery system market will grow by 8.9% annually with a total addressable market cap of $56,139.1 million over 2022-2031, driven by the growing prevalence of ophthalmic diseases, the emerging novel ocular drug delivery systems, rise in number of ophthalmic procedures that require attentive post procedural care, and the increasing demand to deliver controlled dosage forms for pediatric and geriatric population.

In-depth qualitative analyses include identification and investigation of the following aspects:

• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter's Fiver Forces

Based on Product, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.

• Pre-filled Syringes
• Multidose Eyedroppers
• Squeeze Dispensers
• Mist Sprayers
• Contact Lenses
• Ocular Inserts
• Intraocular Implants
• Punctal Plugs
• Other Products

Based on Dosage Form, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.

• Solutions
• Gels
• Ointments
• Suspensions
• Emulsions
• Liposomes & Nanoparticles

By Disease, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.

• Glaucoma
• Diabetic Retinopathy
• Cataract
• Dry Eye Syndrome
• Macular Degeneration
• Diabetic Macular Edema
• Refractive Issues
• Other Diseases

By Setting, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.

• Hospitals
• Clinics
• Homecare Settings
• Ambulatory Surgical Centers (ASCs)
• Other Settings

Geographically, the following national/local markets are fully investigated:

• Japan
• China
• South Korea
• Australia
• India
• Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines)

Selected Key Players

• Aero Pump GmbH
• Allergan plc.
• AptarGroup, Inc.
• Becton, Dickinson and Company
• Biocorp
• Clearside Biomedical, Inc.
• EyePoint Pharmaceuticals, Inc.
• Gaplast GmbH
• Gerresheimer AG
• Jotteq Inc.
• Kedalion Therapeutics, Inc.
• Mati Therapeutics, Inc.
• Nemera
• Nipro Corporation
• Ocular Therapeutix, Inc.
• Ocumedic, Inc.
• Owen Mumford
• Re-Vana Therapeutics
• Silgan Holdings Inc.
• Terumo Corporation
• Valeant Pharmaceuticals International Inc. (Bausch Health Company)
• West Pharmaceutical Services, Inc.

Key Topics Covered:

1 Introduction

2 Market Overview and Dynamics

3 Segmentation of Asia Pacific Market by Product

4 Segmentation of Asia Pacific Market by Dosage Form

5 Segmentation of Asia Pacific Market by Disease

6 Segmentation of Asia Pacific Market by Setting

7 Asia-Pacific Market 2021-2031 by Country

8 Competitive Landscape

For more information about this report visit https://www.researchandmarkets.com/r/vmbl7q